GRITSTONE BIO, INC.

(GRTS)
  Report
Real-time Estimate Cboe BZX  -  05/25 12:14:26 pm EDT
1.745 USD   -2.79%
05/17Gritstone to Participate in H.C. Wainwright Global Investment Conference
AQ
05/11TRANSCRIPT : Gritstone bio, Inc. - Shareholder/Analyst Call
CI
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gritstone Starts Enrollment in Phase 2/3 Trial of Colorectal Cancer Vaccine

01/13/2022 | 07:50am EDT


© MT Newswires 2022
All news about GRITSTONE BIO, INC.
05/17Gritstone to Participate in H.C. Wainwright Global Investment Conference
AQ
05/11TRANSCRIPT : Gritstone bio, Inc. - Shareholder/Analyst Call
CI
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
05/06CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Busin..
GL
05/06CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Busin..
GL
05/05GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/05Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $7.2M, vs. Street Est of $4.21M
MT
05/05Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
AQ
05/05Gritstone bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Op..
GL
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 16,8 M - -
Net income 2022 -125 M - -
Net cash 2022 2,29 M - -
P/E ratio 2022 -1,14x
Yield 2022 -
Capitalization 131 M 131 M -
EV / Sales 2022 7,63x
EV / Sales 2023 -8,71x
Nbr of Employees 201
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,80 $
Average target price 11,33 $
Spread / Average Target 531%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
Erin E. Jones Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-86.04%131
CSL LIMITED-5.70%93 360
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.41%21 450